Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

Matthew Philip Goetz, Katrin Sangkuhl, Henk Jan Guchelaar, Matthias Schwab, Michael Province, Michelle Whirl-Carrillo, W. Fraser Symmans, Howard L. Mcleod, Mark J. Ratain, Hitoshi Zembutsu, Andrea Gaedigk, Ron H. van Schaik, James N. Ingle, Kelly E. Caudle, Teri E. Klein

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.

Original languageEnglish (US)
JournalClinical Pharmacology and Therapeutics
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Cytochrome P-450 CYP2D6
Pharmacogenetics
Tamoxifen
Guidelines
Genetic Polymorphisms
Therapeutics
Parents
Genotype
Breast Neoplasms
Recurrence
Pharmaceutical Preparations
4-hydroxy-N-desmethyltamoxifen

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Goetz, M. P., Sangkuhl, K., Guchelaar, H. J., Schwab, M., Province, M., Whirl-Carrillo, M., ... Klein, T. E. (Accepted/In press). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clinical Pharmacology and Therapeutics. https://doi.org/10.1002/cpt.1007

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. / Goetz, Matthew Philip; Sangkuhl, Katrin; Guchelaar, Henk Jan; Schwab, Matthias; Province, Michael; Whirl-Carrillo, Michelle; Symmans, W. Fraser; Mcleod, Howard L.; Ratain, Mark J.; Zembutsu, Hitoshi; Gaedigk, Andrea; van Schaik, Ron H.; Ingle, James N.; Caudle, Kelly E.; Klein, Teri E.

In: Clinical Pharmacology and Therapeutics, 01.01.2018.

Research output: Contribution to journalArticle

Goetz, MP, Sangkuhl, K, Guchelaar, HJ, Schwab, M, Province, M, Whirl-Carrillo, M, Symmans, WF, Mcleod, HL, Ratain, MJ, Zembutsu, H, Gaedigk, A, van Schaik, RH, Ingle, JN, Caudle, KE & Klein, TE 2018, 'Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy', Clinical Pharmacology and Therapeutics. https://doi.org/10.1002/cpt.1007
Goetz, Matthew Philip ; Sangkuhl, Katrin ; Guchelaar, Henk Jan ; Schwab, Matthias ; Province, Michael ; Whirl-Carrillo, Michelle ; Symmans, W. Fraser ; Mcleod, Howard L. ; Ratain, Mark J. ; Zembutsu, Hitoshi ; Gaedigk, Andrea ; van Schaik, Ron H. ; Ingle, James N. ; Caudle, Kelly E. ; Klein, Teri E. / Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. In: Clinical Pharmacology and Therapeutics. 2018.
@article{afb367f18c36465ba0b76ca47fcf046b,
title = "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy",
abstract = "Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.",
author = "Goetz, {Matthew Philip} and Katrin Sangkuhl and Guchelaar, {Henk Jan} and Matthias Schwab and Michael Province and Michelle Whirl-Carrillo and Symmans, {W. Fraser} and Mcleod, {Howard L.} and Ratain, {Mark J.} and Hitoshi Zembutsu and Andrea Gaedigk and {van Schaik}, {Ron H.} and Ingle, {James N.} and Caudle, {Kelly E.} and Klein, {Teri E.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/cpt.1007",
language = "English (US)",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

AU - Goetz, Matthew Philip

AU - Sangkuhl, Katrin

AU - Guchelaar, Henk Jan

AU - Schwab, Matthias

AU - Province, Michael

AU - Whirl-Carrillo, Michelle

AU - Symmans, W. Fraser

AU - Mcleod, Howard L.

AU - Ratain, Mark J.

AU - Zembutsu, Hitoshi

AU - Gaedigk, Andrea

AU - van Schaik, Ron H.

AU - Ingle, James N.

AU - Caudle, Kelly E.

AU - Klein, Teri E.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.

AB - Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.

UR - http://www.scopus.com/inward/record.url?scp=85041238598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041238598&partnerID=8YFLogxK

U2 - 10.1002/cpt.1007

DO - 10.1002/cpt.1007

M3 - Article

C2 - 29385237

AN - SCOPUS:85041238598

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

ER -